Clinical Trials

Do you have chronic bronchitis and COPD and want to improve treatment? This study will be testing how well a medicine called ivacaftor that is used to treat cystic fibrosis works also to treat symptoms of chronic bronchitis. New research suggests chronic bronchitis may be due to a problem similar to cystic fibrosis. To participate in this study, you must be 40 to 80 years old, have a history of smoking, and have not been diagnosed with asthma or cystic fibrosis. This study will be conducted in Birmingham, Alabama.

Do you have COPD? This study will be looking for genes that may play a role in the development of COPD by looking at the blood from patients who have COPD, as well as the blood from those patients’ family members. To participate in this study, you must be 52 years old or younger and must not be pregnant or have other serious lung diseases such as lung cancer. This study will be conducted in Boston, Massachusetts.

Are you a healthy adult or someone with a history of lung infections such as pneumonia or bronchitis? This study aims to compare fluid and tissue samples from the nose and lungs of healthy adults with people who have a lung disease. Researchers hope to learn why some people are more susceptible to certain infections. This study is located at the NIH Clinical Center in Bethesda, Maryland.

Have you received treatment from a doctor for COPD that has gotten worse and have you been referred for pulmonary rehabilitation, which can help ease the symptoms of COPD.? In this study, researchers are comparing two ways to encourage people to participate in pulmonary rehabilitation. Participants must be at least 40 years old and be willing to participate in calls with a peer coach and view videos. The study is taking place in Springfield, Massachusetts.

Are you an adult who has received urgent care for moderate to serious COPD in the past 4 weeks? This study aims to find out whether a method called Comprehensive Health Informatics Engagement Framework for Pulmonary Rehabilitation can help people who have COPD stick to their treatment plan. To participate in this study, you must be at least 18 years old. This study takes place in New York, New York.

his trial will evaluate an oral drug discovered in a high throughput screen, which increases fetal globin protein (HbF and red blood cells expressing HbF)and messenger ribonucleic acid (mRNA) to high levels in anemic nonhuman primates and in transgenic mice.

Sickle Cell Disease (SCD) impairs oxygen transport to tissue and causes endothelial injury. Thus, therapeutic interventions aim to improve both, but there is an unmet need for biomarkers to determine when intervention is necessary and evaluate the effectiveness of the chosen intervention in individual patients. This study proposes to monitor SCD and its treatment through their impact on cerebral hemodynamics, as the brain is one of the most vulnerable and consequential targets of the disease. Specifically, this study will optimize quantitative magnetic resonance imaging (MRI) and advanced optical spectroscopy techniques such as frequency-domain near-infrared and diffuse correlation spectroscopies (FDNIRS-DCS) to monitor 1) cerebral oxygen transport with measures of cerebral blood flow (CBF), cerebral oxygen extraction fraction (OEF) and cerebral metabolic rate of oxygen consumption (CMRO2) and 2) endothelial function with cerebrovascular reactivity (CVR).

The main goal of this study is to determine whether the treatment will lead to a complete absence of severe vaso-occlusive events (VOEs) in patients with severe SCD.

Are you or your child at least 13 years old and have sickle cell disease? In this stidy, researchers are trying to find out if a new medication improves the success of a blood stem cell transplant. People 13 years old or older who are eligible for a blood stem cell transplant to treat sickle cell disease may be able to participate. Healthy family members over age 13 who are matched to transplant recipients are also needed to donate blood for the study. This study is taking place at the National Institutes of Health Clinical Center in Bethesda, Maryland.

This study is seeking to determine the safety and tolerability of dronabinol use in adults with SCD compared to placebo.